Contact this trialFirst, we need to learn more about you.
Cytotoxic agent
Sitravatinib + Nivolumab for Advanced Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Scarborough, Maine
This trial will compare the effectiveness of sitravatinib when given with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression after platinum-based chemotherapy and checkpoint inhibitor therapy.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.